Plain-English translation of NCT05932680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether patients with relapsed or hard-to-treat multiple myeloma can stop taking teclistamab after it has successfully shrunk their cancer, rather than continuing the medication indefinitely. Teclistamab is a newer type of immunotherapy that helps your own immune cells fight cancer. The study wants to see if taking breaks from the medication—and restarting only if cancer returns—works just as well as staying on it continuously.
Most patients on this medication take it forever to prevent their cancer from coming back, but long-term treatment can increase infection risk and may lead to cancer cells that resist the drug. This trial explores whether giving patients a break from the medication after it works well might reduce these risks while still keeping their cancer under control.
You likely qualify if…
You likely don't qualify if…
You will stop taking teclistamab and enter a monitored surveillance period where doctors will closely watch your cancer markers through blood tests and imaging. If blood work or symptoms suggest your cancer is growing back, you will restart the medication. The study will follow you for at least several months to see how well your cancer stays controlled without continuous treatment, and some participants will also provide additional blood and bone marrow samples to help researchers understand who benefits most from this approach.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States